The decentralized approval procedure of clopidogrel developed by Cimex AG (original product: Plavix® / Iscover® by Bristol-Myers Squibb / Sanofi-Aventis) has successfully been completed.
“Clopidogrel developed by Cimex is the first alternative of this valuable medication available in Germany. We expect shortly a positive ruling from the German authorization agency for medicines and we plan to launch clopidogrel throughout the European Union in cooperation with marketing partners. A first license agreement with a major generics company was already concluded and the signing of a contract with another generics provider is imminent. We expect first sales already in the current quarter”, said Luzi A. von Bidder, Chairman of Schweizerhall Holding AG.
The details can be read here.
No comments:
Post a Comment